formerly Helomics

Helomics, now part of Predictive Oncology, is a precision oncology company that focuses on personalizing cancer therapies through artificial intelligence. It operates the world's largest commercial biobank, containing over 150,000 tumor samples from various cancer types, including ovarian, head and neck, colon, and pancreas cancers. Founded in 1995, Helomics employs around 65 people and has reported revenue of $37.1 million. The company offers a range of services, including a Precision Oncology Platform that provides evidence-based therapy roadmaps for oncologists. Its TruTumor™ Patient-Derived Tumor Models utilize multi-omics assays and the AI-powered D-CHIP platform to support drug development. Additionally, Helomics has developed PeDAL, a predictive diagnostic tool that enhances early drug discovery by testing AI-generated drug-tumor pairings. The company collaborates with institutions like UPMC Magee-Women’s Hospital and ChemImage to advance personalized medicine and develop predictive models for drug responses.